BeGraft Aortic Stents: A European Multi-Centre Experience Reporting Acute Safety and Efficacy Outcomes for the Treatment of Vessel Stenosis in Congenital Heart Diseases.
Micol RebonatoMara PilatiSophie Malekzadeh MilaniDamien BonnetEmma PascallMatthew I JonesPedro BetrianLisa BiancoHugues LucronSébastien HascoetAlban-Elouen BaruteauLuca GiugnoGianfranco ButeraPublished in: Journal of cardiovascular development and disease (2024)
The BeGraft stent can be used safely and effectively in a wide spectrum of congenital heart diseases. Whether these good results will be stable in the longer term still needs to be investigated in a follow-up given its recent introduction into clinical practice, in particular regarding stent fracture or neointimal proliferation.
Keyphrases
- clinical practice
- aortic dissection
- liver failure
- preterm infants
- aortic valve
- respiratory failure
- left ventricular
- vascular smooth muscle cells
- drug induced
- heart failure
- smooth muscle
- pulmonary artery
- emergency department
- intensive care unit
- mass spectrometry
- atomic force microscopy
- atrial fibrillation
- hepatitis b virus
- coronary artery
- angiotensin ii
- pulmonary arterial hypertension
- electronic health record